Apollomics’ $124.2 Million Series C Financing

Goodwin Procter LLP advised Apollomics, Inc. on the deal. Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, announced…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here